Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140023/S033

cobas KRAS Mutation Test

Roche Molecular Systems, Inc. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP140023/S033

What did the FDA decide?

The FDA recorded a 30-Day Notice supplement, P140023/S033, for the cobas® KRAS Mutation Test, a somatic gene mutation detection system in the pathology specialty under product code OWD. The applicant is Roche Molecular Systems, Inc. The listed decision is OK30, dated 2026-10-27.

The recorded statement describes a change to the manufacturing process for oligonucleotides. This supplement concerns that process change, categorized as a manufacturer, sterilizer, packager or supplier change, and does not represent approval of the whole test system. The source record includes no supporting documents, so the specific oligonucleotides, process steps and any performance data remain unknown.

FDA approval order statement

to change the manufacturing process for oligonucleotides
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Oct 27, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140023/S033
Regulatory pathway
PMA supplement
Product code
OWD
Decision code
OK30
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

For the original device and its historical approval scope, see PMA P140023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140023 · Original PMA

    COBAS KRAS MUTATION TEST

  2. P140023/S033 received

    Application receipt date recorded by FDA.

  3. P140023/S033 · FDA decision

    30-Day Notice

  4. P140023/S034 · Related supplement

    Roche cobas KRAS Mutation Test

Timeline entries are records held by MedtechLedger for P140023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140023

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA approvalMay 7, 2015FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
RochePMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records